|

Lurbinectedin Clinical Trials

14 actively recruiting trials across 10 locations

Also known as: JZP712, PM01183, Zepzelca

Pipeline

Phase 1: 2Phase 2: 5Phase 3: 3Phase 1/2: 4

Top Sponsors

  • National Cancer Institute (NCI)2
  • VA Office of Research and Development1
  • UNC Lineberger Comprehensive Cancer Center1
  • PharmaMar1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer14
  • Lung Cancer9
  • Small Cell Lung Cancer4
  • Desmoplastic Small Round Cell Tumor2
  • Relapsed Small Cell Lung Cancer2

Other2 trials

Clinical Study in Patients With DSRCT
Phase 2
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3

Los Angeles, California2 trials

Lurbinectedin in FET-Fused Tumors

Cedars-Sinai Medical Center

Phase 1/2
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Children's Hospital of Los Angeles

Phase 1/2

Bethesda, Maryland2 trials

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

National Institutes of Health Clinical Center

Phase 1/2
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Institutes of Health Clinical Center

Phase 2

Phoenix, Arizona1 trial

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Mayo Clinic Hospital - Phoenix

Phase 3

Springdale, Arkansas1 trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Highlands Oncology Group

Phase 3

Palo Alto, California1 trial

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

VA Palo Alto Health Care System, Palo Alto, CA

Phase 1/2

New Haven, Connecticut1 trial

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Yale University School of Medicine /ID# 278181

Phase 2

Atlanta, Georgia1 trial

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

Emory University Hospital Midtown

Phase 1

Lebanon, New Hampshire1 trial

Study of Trilaciclib and Lurbinectidin

Dartmouth Hitchcock Medical Center

Phase 2

Philadelphia, Pennsylvania1 trial

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2

Houston, Texas1 trial

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.